AR antagonist 17

AR antagonist 17 is a selective, orally active androgen receptor (AR) antagonist with limited ability to cross the blood-brain barrier (IC50 = 0.010 μM) . It effectively inhibits AR dimerization and nuclear translocation, demonstrating strong efficacy in various castration-resistant prostate cancer (CRPC) cells. AR antagonist 17 shows excellent effectiveness against various resistant AR mutants. It also suppresses tumor growth without notable toxicity in LNCaP xenograft models. AR antagonist 17 is useful for research in castration-resistant prostate cancer (CRPC) .